Lamivudine zidovudine: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__" |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Lamivudine zidovudine}} | |||
'''''For patient information, click <u>[[Lamivudine and Zidovudine(patient information)|here]]</u>'''''. | |||
{{CMG}} | |||
==Overview== | |||
==Category== | |||
Antiretroviral | |||
==US Brand Names== | |||
COMBIVIR<sup>®</sup> | |||
==FDA Package Insert== | |||
''' [[Lamivudine zidovudine description|Description]]''' | |||
'''| [[Lamivudine zidovudine clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Lamivudine zidovudine microbiology|Microbiology]]''' | |||
'''| [[Lamivudine zidovudine indications and usage|Indications and Usage]]''' | |||
'''| [[Lamivudine zidovudine contraindications|Contraindications]]''' | |||
'''| [[Lamivudine zidovudine warnings and precautions|Warnings and Precautions]]''' | |||
'''| [[Lamivudine zidovudine adverse reactions|Adverse Reactions]]''' | |||
'''| [[Lamivudine zidovudine drug interactions|Drug Interactions]]''' | |||
'''| [[Lamivudine zidovudine overdosage|Overdosage]]''' | |||
'''| [[Lamivudine zidovudine clinical studies|Clinical Studies]]''' | |||
'''| [[Lamivudine zidovudine dosage and administration|Dosage and Administration]]''' | |||
'''| [[Lamivudine zidovudine how supplied|How Supplied]]''' | |||
'''| [[Lamivudine zidovudine labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
'''Lamivudine''': Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ. | |||
'''Zidovudine''': Intracellularly, zidovudine is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture.<ref>{{Cite web | last = | first = | title = DailyMed: Search | url = http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=COMBIVIR&x=-1146&y=-136 | publisher = | date = | accessdate = 10 January 2014 }}</ref> | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Latest revision as of 03:05, 10 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Category
Antiretroviral
US Brand Names
COMBIVIR®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Lamivudine: Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. 3TC-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ.
Zidovudine: Intracellularly, zidovudine is phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture.[1]
References
- ↑ "DailyMed: Search". Retrieved 10 January 2014.